Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus from International Myeloma Foundation Expert Roundtable

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor

(2020) Joseph Mikhael et al.   Clinical Lymphoma Myeloma & Leukemia

Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma

(2020) Shambavi Richard et al.   Future Oncology

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer

(2017) Arjun Gupta et al.   Journal of Thoracic Oncology

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells

(2014) Jennifer Yang et al.   PLoS One

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA